Siemens Healthineers Logo
DE000SHL1006
SHL100
0PMJ.L

Siemens Healthineers

Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Healthineers will drop the Siemens name going forward

    Siemens Healthineers will pay €300 million for the three-year transition period and will then operate independently under the name Healthineers. The renaming is intended to create transparency, avoid confusion with the parent company, and reflect its successful path as an independent business. The transition should be easy, since the company has already used the Healthineers name element since 2016. » Mere på faz.net


  • Healthineers separates from Siemens and focuses on imaging and precision therapy

    Siemens will reduce its stake in Healthineers by 30 percentage points; the spin-off is to be approved by shareholders of both companies in 2027. Healthineers will change its name during a three-year transition period and pay €300 million for this; at the same time the board proposes a dividend of €1 per share. The diagnostics division will be spun off and renamed Olyrian Diagnostics, affecting about one in five employees; the general ultrasound business will be discontinued. The company is launching a cost program and expects revenue growth of 4–5% and earnings per share of €2.20–2.40 for the new fiscal year. » Mere på faz.net


  • Siemens Healthineers drops "Siemens" and prepares spin-off of lab division

    The medical-technology group intends to rename itself simply Healthineers within three years; the annual general meeting in February 2027 must still formally approve this. Siemens will reduce its stake to a minority and transfer around 30% of the shares to Siemens shareholders. The lab diagnostics division is to be gradually renamed Olyrian Diagnostics and spun off or sold. To offset the additional costs associated with the separation, Healthineers is launching the efficiency program "Transform4 Future" for 2028–2030; the outlook calls for comparable revenue growth of 4–5% and adjusted earnings per share of €2.20–2.40. » Mere på manager-magazin.de


  • Siemens Healthineers: one-year loss of 15.46% on investment made a year ago

    If €1,000 had been invested in Siemens Healthineers a year ago, investors would have €845.36 today, a loss of 15.46%. The stock closed on Oct. 21, 2026 at €41.71; a year earlier the price was €49.34. Market capitalization most recently €46.38 billion; calculation does not account for splits or dividends. » Mere på finanzen.net


  • Siemens Healthineers: analysts see Q3 quarter with €0.673 EPS and revenue of €6.78 billion

    Siemens Healthineers is expected to publish figures for the quarter ended 30 September 2026 on 5 November 2026. Ten analysts on average expect earnings per share of €0.673 (previous year: €0.520), and nine analysts see revenue rising by about 7.19% to €6.78 billion (previous year: €6.32 billion). For the recently ended fiscal year, 21 analysts forecast average earnings per share of €2.35 and 20 analysts forecast revenue of €23.57 billion. » Mere på finanzen.net

I 2026 har Siemens Healthineers allerede udloddet 1,00 € i udbytte. Den seneste udlodning fandt sted i februar.

Virksomhedstal

I det seneste kvartal havde Siemens Healthineers en omsætning på 5,76 mia. € og et nettoresultat på 669 mio. €
(EUR) juni 2026
YoY
Omsætning 5,76 mia. 1,80 %
Bruttofortjeneste 2,45 mia. 12,33 %
Nettoresultat 669 mio. 21,20 %
EBITDA 1,33 mia. 9,67 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
48,18 mia. €
Antal aktier
1,12 mia.
Højeste/laveste i 52 uger
47,25 € - 32,82 €
Udbytteafkast
2,30 %
Udbytte TTM
1,00 €
Beta
0,83
P/E (PE Ratio)
21,69
PEG (PEG Ratio)
5,92
K/I (PB Ratio)
2,40
P/S (PS Ratio)
2,03

Virksomhedsprofil

Siemens Healthineers AG udvikler, fremstiller og sælger gennem sine datterselskaber en række diagnostiske og terapeutiske produkter og services til sundhedsudbydere over hele verden. Selskabet er organiseret i fire segmenter: Imaging, Diagnostics, Varian og Advanced Therapies. Imaging-segmentet leverer magnetisk resonans-skanning, computertomografi, røntgensystemer, molekylær billeddannelse og ultralydssystemer. Diagnostics-segmentet tilbyder in vitro-diagnostiske produkter og services til sundhedsudbydere inden for laboratorie-, molekylær- og point-of-care-diagnostik samt workflow-løsninger til laboratorier og informatikprodukter. Varian-segmentet leverer teknologier, løsninger og services til kræftbehandling til onkologiske afdelinger på hospitaler og klinikker; samt teknologibaserede optimerede workflows, kliniske services og konsulentydelser og digitale løsninger og applikationer til styring af behandling og terapi. Advanced Therapies-segmentet tilbyder produkter, der er designet til at understøtte billedstyrede, minimalt invasive behandlinger inden for områder som kardiologi, interventionel radiologi og kirurgi; samt angiografisystemer og mobile C-arms, herunder en robotassisteret platform til endovaskulære koronare og perifere vaskulære interventioner. Segmentet tilbyder desuden udstyrsydelsesstyring, klinisk uddannelse og e-learning, aktivstyring og administrerede afdelingsservices til laboratorier og sundhedsfaciliteter samt konsulent- og digitale sundhedsservices. Selskabet har hovedkontor i Erlangen, Tyskland. Siemens Healthineers AG er et datterselskab af Siemens Aktiengesellschaft.

Navn
Siemens Healthineers
CEO
Bernhard Montag
Hjemsted Forchheim, bv
Tyskland
Websted
Sektor
Sundhed
Branche
Sundhedsudstyr og -produkter
Børsnotering
20.05.2020
Medarbejdere 74.000

Tickersymboler

Børs Symbol
London Stock Exchange
0PMJ.L
XETRA
SHL.DE
Pnk
SEMHF
Frankfurt
SHL.F
Düsseldorf
SHL.DU
Hamburg
SHL.HM
Milan
1SHL.MI
London
0PMJ.L
SIX
SHL.SW
München
SHL.MU
Wien
SHL.VI
🍪

Parqet  bruger cookies. Læs mere